TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX)

CUSIP: 89854M101

Q3 2025 13F Holders as of 30 Sep 2025

Type / Class
Equity / Voting Common Stock, par value $0.0001 per share
Shares outstanding
52,382,313
Total 13F shares
34,601,160
Share change
-1,129,874
Total reported value
$62,910,264
Price per share
$1.82
Number of holders
72
Value change
-$1,894,623
Number of buys
22
Number of sells
42

Quarterly Holders Quick Answers

What is CUSIP 89854M101?
CUSIP 89854M101 identifies TCRX - TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of TCRX - TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
EcoR1 Capital, LLC
3/4/5 13D/G
10%+ Owner
1.3%
from 13D/G
5,000,000
$24,842,500 26 May 2023
Lynx1 Capital Management LP
13D/G 13F
Company
15%
7,857,347
$11,393,153 +$3,625,000 30 Jun 2025
Christoph H. Westphal
3/4/5
10%+ Owner
class O/S missing
2,193,472
$10,898,266 20 Jul 2021
BIOTECHNOLOGY VALUE FUND L P
13D/G
BVF PARTNERS L P/IL
10%
5,263,541
$8,421,666 $0 31 Mar 2025
BVF INC/IL
13F
Company
10%
5,226,074
$7,577,807 30 Jun 2025
13F
K2 HealthVentures Equity Trust LLC
13D/G
6.9%
3,602,700
$5,764,320 $0 31 Dec 2024
ADAGE CAPITAL PARTNERS GP, L.L.C.
13D/G
Adage Capital Management, L.P.
7.1%
3,500,000
$5,600,000 $0 31 Dec 2024
BAKER BROS. ADVISORS LP
13F 3/4/5
Company · Director
5.3%
2,784,792
$4,037,948 30 Jun 2025
BlackRock, Inc.
13F 13D/G
Company
1.8%
from 13D/G
2,566,524
$3,721,460 30 Jun 2025
VANGUARD GROUP INC
13F
Company
4.1%
2,149,376
$3,116,595 30 Jun 2025
13F
Propel Bio Management, LLC
13F
Company
4%
2,087,139
$3,026,352 30 Jun 2025
13F
Adage Capital Management, L.P.
13D/G
2.5%
1,350,000
$1,957,500 $0 30 Jun 2025
Deer Management Co. LLC
13F
Company
2.4%
1,245,504
$1,805,981 30 Jun 2025
13F
Alphabet Inc.
13F
Company
2.1%
1,077,080
$1,561,766 30 Jun 2025
13F
Simplify Asset Management Inc.
13F
Company
2%
1,046,916
$1,518,028 30 Jun 2025
13F
Aberdeen Group plc
13F
Company
1.7%
891,448
$1,292,600 30 Jun 2025
13F
MORGAN STANLEY
13F
Company
1.6%
853,346
$1,237,352 30 Jun 2025
13F
RENAISSANCE TECHNOLOGIES LLC
13F
Company
1.5%
792,056
$1,148,481 30 Jun 2025
13F
MILLENNIUM MANAGEMENT LLC
13F
Company
1.2%
630,138
$913,700 30 Jun 2025
13F
DC Funds, LP
13F
Company
1.2%
630,000
$913,500 30 Jun 2025
13F
TANG CAPITAL MANAGEMENT LLC
13F
Company
1.1%
600,000
$870,000 30 Jun 2025
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
1.1%
566,371
$821,529 30 Jun 2025
13F
GOLDMAN SACHS GROUP INC
13F
Company
0.82%
430,070
$623,602 30 Jun 2025
13F
UBS Group AG
13F
Company
0.76%
400,401
$580,581 30 Jun 2025
13F
TWO SIGMA INVESTMENTS, LP
13F
Company
0.7%
365,034
$529,299 30 Jun 2025
13F
Timothy J. Barberich
3/4/5
Director
mixed-class rows
135,286
mixed-class rows
$498,271 18 Dec 2023
JPMORGAN CHASE & CO
13F
Company
0.55%
287,743
$417,227 30 Jun 2025
13F
Barbara Klencke
3/4/5
Director
mixed-class rows
137,000
mixed-class rows
$370,300 30 Jun 2025
CITADEL ADVISORS LLC
13F
Company
0.42%
218,987
$317,532 30 Jun 2025
13F
BANK OF AMERICA CORP /DE/
13F
Company
0.42%
217,967
$316,052 30 Jun 2025
13F
TWO SIGMA ADVISERS, LP
13F
Company
0.41%
214,400
$310,880 30 Jun 2025
13F
JANE STREET GROUP, LLC
13F
Company
0.41%
213,396
$309,424 30 Jun 2025
13F
STATE STREET CORP
13F
Company
0.38%
200,513
$290,744 30 Jun 2025
13F
Cubist Systematic Strategies, LLC
13F
Company
0.33%
172,512
$250,142 30 Jun 2025
13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC
13F
Company
0.29%
153,700
$222,865 30 Jun 2025
13F
Troluce Capital Advisors LLC
13F
Company
0.29%
150,000
$217,500 30 Jun 2025
13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP
13F
Company
0.28%
144,372
$209,339 30 Jun 2025
13F
BROWN BROTHERS HARRIMAN & CO
13F
Company
0.27%
143,051
$207,424 30 Jun 2025
13F
DIMENSIONAL FUND ADVISORS LP
13F
Company
0.25%
129,856
$188,167 30 Jun 2025
13F
STIFEL FINANCIAL CORP
13F
Company
0.22%
115,941
$168,114 30 Jun 2025
13F
NewEdge Wealth, LLC
13F
Company
0.17%
91,463
$150,914 30 Jun 2025
13F
NORTHERN TRUST CORP
13F
Company
0.19%
98,548
$142,895 30 Jun 2025
13F
LETKO, BROSSEAU & ASSOCIATES INC
13F
Company
0.18%
95,875
$139,019 30 Jun 2025
13F
Militia Capital Partners, LP
13F
Company
0.18%
94,300
$136,735 30 Jun 2025
13F
Y-Intercept (Hong Kong) Ltd
13F
Company
0.15%
76,660
$111,157 30 Jun 2025
13F
Qube Research & Technologies Ltd
13F
Company
0.13%
68,286
$99,015 30 Jun 2025
13F
HRT FINANCIAL LP
13F
Company
0.11%
55,369
$80,000 30 Jun 2025
13F
MARSHALL WACE, LLP
13F
Company
0.1%
53,678
$77,833 30 Jun 2025
13F
Jain Global LLC
13F
Company
0.07%
37,888
$54,938 30 Jun 2025
13F
DC Investments Management, LLC
13F
Company
0.07%
35,563
$51,566 30 Jun 2025
13F

Institutional Holders of TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) as of Q3 2025

As of 30 Sep 2025, TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) was held by 72 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 34,601,160 shares. The largest 10 holders included Lynx1 Capital Management LP, BVF INC/IL, BAKER BROS. ADVISORS LP, BlackRock, Inc., VANGUARD GROUP INC, Propel Bio Management, LLC, Aberdeen Group plc, Deer Management Co. LLC, Alphabet Inc., and Simplify Asset Management Inc.. This page lists 72 institutional shareholders reporting positions in this security for the Q3 2025 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q3 2025 vs Q2 2025 Across Filers

Q2 2025 holders
79
Q3 2025 holders
72
Holder diff
-7
Investor Q2 2025 Shares Q3 2025 Shares Share Diff Share Chg % Q2 2025 Value $ Q3 2025 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .